Samaha Eli reported other involving 9,167,489 shares of Theravance Biopharma, Inc. at $17.00 for −$156M on Sep 23, 2026

Other
Form 4 code J. Other acquisition or disposition. The filer must describe the transaction.
10% owner
10%
Filed Nov 16, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$155,847,313Shares × reported price
Shares traded
9,167,489COM
Price per share
$17.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
0Indirect · See Footnotes
Trade date
Sep 23, 2026Other
Filed
Nov 16, 2026, 10:53 AM ET54-day reporting delay
Accession
0001013594-26-001191Code J · Transaction 401721
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

Filing warnings

Notes recorded with this filing
2 warnings
delayed filingThe filing was reported 54 calendar days after the transaction date.
ambiguous transaction codeThe transaction code is missing or represents other activity; review the filing and footnotes.

TBPH price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
TBPH · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 23, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −0.1%1w ago 0%1d ago 0%
Returns since7d30d90d180d1y

Footnotes in full

F1: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time. F2: These shares are held by funds managed by Madison Avenue Partners, LP. The Reporting Person is the non-member manager of Madison Avenue GP, LLC, the managing member of EMAI Management, LLC, and the majority owner of Caraway Jackson Investments LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of the pecuniary interest of the Reporting Person therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, the Reporting Person is the beneficial owner of such securities.